Swedencare

Swedencare missed consensus estimates in the second quarter of 2026: net revenue SEK 670m (-4% versus consensus) and operating EBITDA SEK 129m (-5% versus forecasts). The stock slid intraday by around 15.7% to SEK 21.8 and reached a 52-week low of SEK 21.35. Weighing on the results were an organic decline in North America of 3% after delays in product launches through the FDMC channel and a weak market environment, which increases the risk of target-price revisions. » Więcej na de.investing.com

At the capital markets day Swedencare reiterated targets of double‑digit organic growth and a mid‑term operating EBITDA margin above 26%, as well as a leverage target of below two times. Management cited drivers such as online sales, direct sales, retail and a strategic focus on the higher‑margin CDMO business, although its impact on the product mix remains uncertain. Margin improvement is expected mainly in the second half of the forecast period, driven by normalization of conversion costs and scale effects in pharmaceutical manufacturing. Analysts note that the investment case now depends on execution of the operational plans; the stock had underperformed year‑to‑date. » Więcej na de.investing.com

SwedenCare reports Q1 net sales of SEK 650m (+1% y/y, +11% organically), broadly in line with analyst expectations. Operating EBITDA rose to SEK 128m (+3% y/y) with a margin of 19.6%, but the result was 3% below consensus, weighed down by higher external costs (including Amazon-related expenses and trade show participation). Operating EBIT remained at SEK 103m, in line with the prior year, and the EBIT margin fell slightly to 15.8%. Growth came mainly from Europe and the production segment, while North America showed weaker volumes; dental and pharma posted strong gains, nutraceuticals declined. Management sees stable demand in core markets and plans to normalize cost levels in the second half of the year. » Więcej na de.investing.com